search
Back to results

Low-Frequency REpetitive TRanscranial Magnetic Stimulation Combined With Endovascular Treatment in ACute Ischemic StrokE (RETRACE-II)

Primary Purpose

Stroke, Acute Ischemic

Status
Not yet recruiting
Phase
Not Applicable
Locations
China
Study Type
Interventional
Intervention
LF-rTMS
Sham stimulation
Sponsored by
Beijing Tiantan Hospital
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Stroke, Acute Ischemic focused on measuring Acute ischemic stroke, LF-rTMS, Endovascular therapy, Phase 2 Pilot Trial

Eligibility Criteria

18 Years - 80 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria: 18 - 80 years, male or female; Clinically diagnosed as acute anterior ischemic stroke, artery occlusion occurred at the terminal of the intracranial carotid artery, T-shaped bifurcation or M1 segment of the middle cerebral artery; Within 24 hours of stroke onset; Eligible for other imaging indications for bridging therapy or direct mechanical thrombectomy: ASPECTS ≥6 certified by the latest brain CT imaging; Patients within 6-16 hours after stroke onset should meet the mismatch criteria, which was defined as infarction core volume <70 ml, mismatch ratio ≥1.8 and the ischemic volume > 15 ml (DEFUSE-3 Criteria); or NIHSS score ≥ 10 with infarction -core volume < 31 cm3, or NIHSS score ≥ 20 with infarction core volume ≤ 51 cm3 (DAWN Criteria); Patients within 16-24 hours after stroke onset should meet the mismatch criteria, which was defined as NIHSS score ≥ 10 with infarction-core volume < 31 cm3, or NIHSS score ≥ 20 with infarction-core volume ≤ 51 cm3 (DAWN Criteria); Planned to receive bridging therapy (endovascular therapy after intravenous alteplase) or direct endovascular therapy; Pre-morbid modified Rankin Scale ≤1; 6 ≤ NIHSS ≤ 25 before endovascular therapy; Signed informed consent from subjects or legally authorized representatives Exclusion Criteria: TMS contraindications include metallic foreign bodies in the head, pacemaker, implantable drug pumps, cochlear implants, etc. Epilepsy or history of epilepsy, intracranial hypertension, tumor and other serious neurological disorders; Midline displacement and brain parenchymal mass effect seen in head CT and other images; Head CT or MRI showed bilateral acute cerebral infarction; CT or MRI showed a large area of infarction (> 1/3 of the area supplied by middle cerebral artery); Evidence of acute intracranial hemorrhage; Before the bridging therapy, other thrombolytic drugs besides alteplase or tenecteplase were used; A history of congenital or acquired hemorrhagic disease, coagulation factor deficiency, or thrombocytopenia disease; After blood pressure control, the systolic blood pressure was still ≥180 mmHg or the diastolic blood pressure was ≥110 mmHg; Known recent or current serum creatinine exceeding 1.5 times the upper limit of normal or estimated glomerular filtration rate (EGFR) < 60 mL/min; Patients during pregnancy or lactation and within 90 days of planned pregnancy; Patients with severe mental disorders or dementia who can not cooperate with informed consent and follow-up; Patients with malignancy or severe systemic disease and expected survival of less than 90 days; Participants in other clinical intervention studies within 30 days before randomization or who were participating in other clinical intervention studies.

Sites / Locations

  • Beijing Tian tan Hospital

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Sham Comparator

Arm Label

LF-rTMS

Sham coil stimulation

Arm Description

Using "8" coil,1-Hz rTMS to stimulate the M1 region of the ipsilateral hemisphere, the stimulation intensity was RMT 100%, 1200pulses/session, two sessions (2400 pulses)/day (interval ≥ 2 hours), lasting 3 days (total 6 sessions, 7200pulses)

The sham stimulation coil was used to stimulate the same site, duration and sound as the LF-rTMS group, ensuring no effective stimulation, twice a day for 3 days

Outcomes

Primary Outcome Measures

Rescue penumbra ratio
Baseline penumbra volume - Infarct volume 3 days after randomization / Baseline penumbra volume × 100%
Early neurological improvement (ENI)
The proportion of patients with a reduction of ≥4 on the NIHSS, compared with the baseline score or an NIHSS of 0 or 1
Symptomatic intracranial hemorrhage
The proportion of symptomatic intracranial hemorrhage

Secondary Outcome Measures

Infarct volume progression
The difference between CT infarct volume and baseline core infarct volume
Final infarct volume
Infarct volume on DWI at day 7 after randomization, and infarct volume on FlAIR at Day 90 ± 7 after randomization.
mRS scores of 0-1
Proportion of patients with mRS scores of 0-1
mRS scores of 0-2
Proportion of patients with mRS scores of 0-2
Secondary brain injury on imaging
Evaluation of cerebral infarction volume on FLAIR and cerebral atrophy
Barthel index of ADL
Barthel index of ADL, 0-100 (higher score indicates better)
EQ-5D-5L
The Health Questionnaire (EQ-5D-5L) is a self-report survey that measures quality of life across 5 domains: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. Each dimension is scored on a 5-level severity ranking that ranges from "no problems" through "extreme problems."
Montreal Cognitive Assessment (MoCA) total score
Total score of the MoCA Performance on the MoCA (0-30; higher score indicates better performance)
Serious adverse events (SAE)
The proportion of serious adverse events (SAE)
All-cause deaths
The proportion of all-cause deaths
Symptomatic intracranial hemorrhage
The incidence of symptomatic intracranial hemorrhage
Deterioration of neurological function
The incidence of deterioration of neurological function (NIHSS increase ≥4 points)
Stroke recurrence
Cerebral infarction, cerebral hemorrhage
Adverse events (AE)
Adverse events (AE)

Full Information

First Posted
August 24, 2023
Last Updated
September 26, 2023
Sponsor
Beijing Tiantan Hospital
search

1. Study Identification

Unique Protocol Identification Number
NCT06064747
Brief Title
Low-Frequency REpetitive TRanscranial Magnetic Stimulation Combined With Endovascular Treatment in ACute Ischemic StrokE
Acronym
RETRACE-II
Official Title
Low-Frequency REpetitive TRanscranial Magnetic Stimulation Combined With Endovascular Treatment in ACute Ischemic StrokE (RETRACE-II): A Randomized, Double-Blind, Sham-Controlled, Phase 2 Pilot Trial
Study Type
Interventional

2. Study Status

Record Verification Date
September 2023
Overall Recruitment Status
Not yet recruiting
Study Start Date
October 8, 2023 (Anticipated)
Primary Completion Date
October 30, 2024 (Anticipated)
Study Completion Date
October 30, 2024 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Beijing Tiantan Hospital

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
Yes

5. Study Description

Brief Summary
This is a multicenter, randomized, double-blind, sham-controlled, investigator-initiated clinical study, to evaluate the clinical efficacy and safety of LF-rTMS in rescuing the ischemic penumbra, reducing disability rate and improving functional outcome in patients with acute ischemic stroke receiving early endovascular recanalization (bridging or direct endovascular therapy)
Detailed Description
The target population of this study was patients with acute ischemic stroke of the anterior circulation diagnosed clinically. The site of acute occlusion of the responsible vessel was located in the intracranial segment of the internal carotid artery, T-type bifurcation or M1 segment of the middle cerebral artery, planning for bridging therapy (bridging intravascular therapy after intravenous thrombolysis with alteplase) or direct intravascular therapy, the time from stroke onset to the start of the trial intervention was less than 24 hours (when the exact time of onset was unknown, the patient's"Last apparent normal time" was defined as the time of onset). Enrolled patients were randomly assigned in a 1:1 ratio to the"LF-rTMS group" or the"Sham Stimulation Group" and received: LF-rTMS group: using "8" coil,1-Hz rTMS to stimulate the M1 region of the ipsilateral hemisphere, the stimulation intensity was RMT 100%, 1200pulses/session, two sessions (2400 pulses)/day (interval ≥ 2 hours), lasting 3 days (total 6 sessions, 7200pulses); Sham stimulation group: the sham stimulation coil was used to stimulate the same site, duration and sound as the LF-rTMS group, ensuring no effective stimulation, twice a day for 3 days. All patients received endovascular therapy (bridging therapy or direct endovascular therapy). All patients were followed up until the 90th day after randomization to evaluate the clinical efficacy and safety of LF-rTMS in rescuing the ischemic penumbra, reducing disability rate and improving functional outcome in patients with acute ischemic stroke receiving early endovascular recanalization (bridging or direct endovascular therapy)

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Stroke, Acute Ischemic
Keywords
Acute ischemic stroke, LF-rTMS, Endovascular therapy, Phase 2 Pilot Trial

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
ParticipantInvestigatorOutcomes Assessor
Masking Description
In order to ensure the blind method, the sham stimulation coil was used, which had the same parameters (including location, stimulation frequency, time, etc.) as the LF-rTMS group, and had the same stimulation sound to ensure no effective stimulation, to ensure the blind state is maintained during the test. Investigators and patients who participated in the study treatment or involved in the clinical evaluation of patients were blinded to treatment grouping.
Allocation
Randomized
Enrollment
60 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
LF-rTMS
Arm Type
Experimental
Arm Description
Using "8" coil,1-Hz rTMS to stimulate the M1 region of the ipsilateral hemisphere, the stimulation intensity was RMT 100%, 1200pulses/session, two sessions (2400 pulses)/day (interval ≥ 2 hours), lasting 3 days (total 6 sessions, 7200pulses)
Arm Title
Sham coil stimulation
Arm Type
Sham Comparator
Arm Description
The sham stimulation coil was used to stimulate the same site, duration and sound as the LF-rTMS group, ensuring no effective stimulation, twice a day for 3 days
Intervention Type
Device
Intervention Name(s)
LF-rTMS
Intervention Description
LF-rTMS group: using "8" coil,1-Hz rTMS to stimulate the M1 region of the ipsilateral hemisphere, the stimulation intensity was RMT 100%, 1200pulses/session, two sessions (2400 pulses)/day (interval ≥ 2 hours), lasting 3 days (total 6 sessions, 7200pulses);
Intervention Type
Device
Intervention Name(s)
Sham stimulation
Intervention Description
Sham stimulation group: the sham stimulation coil was used to stimulate the same site, duration and sound as the LF-rTMS group, ensuring no effective stimulation, twice a day for 3 days.
Primary Outcome Measure Information:
Title
Rescue penumbra ratio
Description
Baseline penumbra volume - Infarct volume 3 days after randomization / Baseline penumbra volume × 100%
Time Frame
3 days
Title
Early neurological improvement (ENI)
Description
The proportion of patients with a reduction of ≥4 on the NIHSS, compared with the baseline score or an NIHSS of 0 or 1
Time Frame
3 days
Title
Symptomatic intracranial hemorrhage
Description
The proportion of symptomatic intracranial hemorrhage
Time Frame
3 days
Secondary Outcome Measure Information:
Title
Infarct volume progression
Description
The difference between CT infarct volume and baseline core infarct volume
Time Frame
3 days
Title
Final infarct volume
Description
Infarct volume on DWI at day 7 after randomization, and infarct volume on FlAIR at Day 90 ± 7 after randomization.
Time Frame
7 and 90 days
Title
mRS scores of 0-1
Description
Proportion of patients with mRS scores of 0-1
Time Frame
90 days
Title
mRS scores of 0-2
Description
Proportion of patients with mRS scores of 0-2
Time Frame
90 days
Title
Secondary brain injury on imaging
Description
Evaluation of cerebral infarction volume on FLAIR and cerebral atrophy
Time Frame
90 days
Title
Barthel index of ADL
Description
Barthel index of ADL, 0-100 (higher score indicates better)
Time Frame
90 days
Title
EQ-5D-5L
Description
The Health Questionnaire (EQ-5D-5L) is a self-report survey that measures quality of life across 5 domains: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. Each dimension is scored on a 5-level severity ranking that ranges from "no problems" through "extreme problems."
Time Frame
90 days
Title
Montreal Cognitive Assessment (MoCA) total score
Description
Total score of the MoCA Performance on the MoCA (0-30; higher score indicates better performance)
Time Frame
90 days
Title
Serious adverse events (SAE)
Description
The proportion of serious adverse events (SAE)
Time Frame
90 days
Title
All-cause deaths
Description
The proportion of all-cause deaths
Time Frame
90 days
Title
Symptomatic intracranial hemorrhage
Description
The incidence of symptomatic intracranial hemorrhage
Time Frame
90 days
Title
Deterioration of neurological function
Description
The incidence of deterioration of neurological function (NIHSS increase ≥4 points)
Time Frame
3 days
Title
Stroke recurrence
Description
Cerebral infarction, cerebral hemorrhage
Time Frame
90 days
Title
Adverse events (AE)
Description
Adverse events (AE)
Time Frame
3 days

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
80 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: 18 - 80 years, male or female; Clinically diagnosed as acute anterior ischemic stroke, artery occlusion occurred at the terminal of the intracranial carotid artery, T-shaped bifurcation or M1 segment of the middle cerebral artery; Within 24 hours of stroke onset; Eligible for other imaging indications for bridging therapy or direct mechanical thrombectomy: ASPECTS ≥6 certified by the latest brain CT imaging; Patients within 6-16 hours after stroke onset should meet the mismatch criteria, which was defined as infarction core volume <70 ml, mismatch ratio ≥1.8 and the ischemic volume > 15 ml (DEFUSE-3 Criteria); or NIHSS score ≥ 10 with infarction -core volume < 31 cm3, or NIHSS score ≥ 20 with infarction core volume ≤ 51 cm3 (DAWN Criteria); Patients within 16-24 hours after stroke onset should meet the mismatch criteria, which was defined as NIHSS score ≥ 10 with infarction-core volume < 31 cm3, or NIHSS score ≥ 20 with infarction-core volume ≤ 51 cm3 (DAWN Criteria); Planned to receive bridging therapy (endovascular therapy after intravenous alteplase) or direct endovascular therapy; Pre-morbid modified Rankin Scale ≤1; 6 ≤ NIHSS ≤ 25 before endovascular therapy; Signed informed consent from subjects or legally authorized representatives Exclusion Criteria: TMS contraindications include metallic foreign bodies in the head, pacemaker, implantable drug pumps, cochlear implants, etc. Epilepsy or history of epilepsy, intracranial hypertension, tumor and other serious neurological disorders; Midline displacement and brain parenchymal mass effect seen in head CT and other images; Head CT or MRI showed bilateral acute cerebral infarction; CT or MRI showed a large area of infarction (> 1/3 of the area supplied by middle cerebral artery); Evidence of acute intracranial hemorrhage; Before the bridging therapy, other thrombolytic drugs besides alteplase or tenecteplase were used; A history of congenital or acquired hemorrhagic disease, coagulation factor deficiency, or thrombocytopenia disease; After blood pressure control, the systolic blood pressure was still ≥180 mmHg or the diastolic blood pressure was ≥110 mmHg; Known recent or current serum creatinine exceeding 1.5 times the upper limit of normal or estimated glomerular filtration rate (EGFR) < 60 mL/min; Patients during pregnancy or lactation and within 90 days of planned pregnancy; Patients with severe mental disorders or dementia who can not cooperate with informed consent and follow-up; Patients with malignancy or severe systemic disease and expected survival of less than 90 days; Participants in other clinical intervention studies within 30 days before randomization or who were participating in other clinical intervention studies.
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Zixiao Li, MD
Phone
+8613683234256
Email
lizixiao2008@hotmail.com
First Name & Middle Initial & Last Name or Official Title & Degree
Lingling Ding, MD
Phone
+8613552358752
Email
dll_ing@sina.com
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Yongjun MD Wang, MD
Organizational Affiliation
Beijing Tiantan Hospital
Official's Role
Principal Investigator
Facility Information:
Facility Name
Beijing Tian tan Hospital
City
Beijing
State/Province
Beijing
ZIP/Postal Code
100070
Country
China

12. IPD Sharing Statement

Plan to Share IPD
No

Learn more about this trial

Low-Frequency REpetitive TRanscranial Magnetic Stimulation Combined With Endovascular Treatment in ACute Ischemic StrokE

We'll reach out to this number within 24 hrs